Baxter Appoints Two Corporate Officers

Baxter Appoints Two Corporate Officers 
DEERFIELD, Ill. - (Business Wire) The Board of Directors of Baxter International Inc. (NYSE:BAX) today elected two new corporate officers of the company.

Mary Kay Ladone, vice president, Investor Relations, has been appointed to serve as an officer of the company. Ladone has served in her current position since 2004. Previously, she held numerous positions with increasing responsibility within the company's finance, business development, and supplier management functions. She joined Baxter in 1988 as a finance associate after graduating with a bachelor of business administration degree from the University of Notre Dame.

Stephanie Shinn, currently associate general counsel for Baxter, has also been named corporate secretary and appointed to serve as an officer of the company. Shinn joined Baxter in 2005 as corporate counsel in the company's Corporate and Securities group and has assumed positions of increasing responsibility. Prior to joining Baxter, Shinn was an associate with Sidley Austin LLP. She received her law degree from Boston College and her undergraduate degree from Smith College. Prior to law school, Shinn worked in the audit function at Deloitte & Touche LLP.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

 

Baxter International Inc.
Media Contact:
Deborah Spak, (847) 948-2349 

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.